Pulmonary hypertension in Bogotá: description of a group of patients belonging to the Institutional Program of the Fundación Neumológica Colombiana
Hipertensión arterial pulmonar en Bogotá: descripción de un grupo de pacientes pertenecientes al Programa Institucional de la Fundación Neumológica Colombiana
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Justification: there is a scarce knowledge about the characteristics of patients with pulmonary hypertension (PH) residing in Bogotá (2.640 meters above sea level). Description of a selected population (not necessarily a representative one) can be an approach to the behavior of PH at this altitude. Objective: to describe some clinical, functional, and hemodynamic characteristics in a selected population with PH classified as belonging to WHO groups 1 (pulmonary arterial hypertension [PAH]) and 4 (pulmonary hypertension due to chronic thrombotic and/or embolic disease [CTEPH]) de la OMS.
Materials and methods: an observational, descriptive, retrospective study, which included patients aged 18 and over seen at the Fundación Neumológica Colombiana (Bogotá [2640 m]), between January 2008 and June 2009. Demographic, clinical, functional, and hemodynamic variables were analyzed (descriptive statistics).
Results: 30 patients were included, 24 (80%) women (43±14 years). Distribution (Dana Point Classification - WHO): Group 1: idiopathic (13%), collagen-vascular (30%), shunts (27%), toxic (3%), hereditary (3%) and portal-pulmonary (7%). Group 4: CTEPH (17%). At the moment of diagnosis, 80% were in functional classes III and IV (NYHA). DLco was normal or slightly reduced. Distance on the six-minute walk test was 442±115 m (64±15% predicted), and
mean pulmonary arterial pressure (PAPm) was severely increased (54±16 mmHg).
Conclusion: diagnosis at advanced stages is documented (FC III and IV [80%]), with severe hemodynamic compromise (PAPm 54±16) and moderate stress limitation. It is necessary to clarify whether altitude influences this behavior.
Article visits 206 | PDF visits 277
Downloads
- Barst R, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and Differential Assessment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
- Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension. In: Rubin L, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker, 1997:83129.
- D'Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-9.
- Rich S, Danzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107: 216-23.
- Rubin LJ, Badesch DB, Barst RJ, Galié N, Black C, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
- Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension.N Engl J Med 2005; 353(20): 2148-57.
- Olschewski H, Simonneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
- Rich S, Brundage B, Levy P. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985; 71(6): 1191-6.
- Barberá JA. Estándares asistenciales en hipertensión pulmonar. Documento de consenso elaborado por la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y la Sociedad Española de Cardiología (SEC). Arch Bronconeumol. 2008; 44(2):87-99
- Rabinovitch M, Konstam MA, Gamble WJ, et al. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ Res 1983; 52: 432-41.
- Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(1 Suppl): S43-54.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
- MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, et al. 18 Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720-35.
- Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20: 1314-31.
- ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
- Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14:270-4.
- D'Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-9.
- Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical Correlates and Prognostic Significance of Sixminute Walk Test in Patients with Primary Pulmonary Hypertension. Am J Respir Crit Care Med 2000; 161: 287-492.
- Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107(2): 216-23.
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary Arterial Hypertension in France. Am J Respir Crit Care Med 2006; 173: 1023-30.
- Sun XG, Hansen JE, Oudiz RJ, and Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41(6):1028-35.
- Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and Survival Study in Chinese Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Chest 2007; 132: 373-9.
- McLaughlin VV, Presberg KW, Doyle RL, Abman SH, Mc-Crory DC, Fortin T, Ahearn G. Prognosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126: 78S-92S.
Information
Journal history
Keywords
QR code
Funding
Directories and indexes
